Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into the third and final
Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.
After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.
Our live coverage from this year’s slimmed down, virtual version of the American Society of Clinical Oncology (ASCO) annual meeting continues at 8am (ET) as we move into day 2 of the oncolo
Bristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough competition from a rival Johnson & Johnson drug, accord
With an FDA approval for HER2-positive breast cancer already in the bag, Daiichi Sankyo and AstraZeneca’s Enhertu now looks like it may be able to add lung, stomach and colorec